Dr. Khorana has disclosed that he is on the steering committee for LEO Pharma Inc. and is a consultant for sanofi-aventis. He also receives research support from the Sondra and Stephen Hardis Endowed Chair in Oncology. This work was previously supported by grants from the National Cancer Institute (K23 CA120587); the National Heart, Lung and Blood Institute (R01HL095109); and the V Foundation.
Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network
Ms. Green has disclosed that she has no relevant financial relationships.
Deborah J. Moonan, RN, BSN, Manager, CE Supporter Outreach
Ms. Moonan has disclosed the following relationship with commercial interests: AstraZeneca: Stockholder/Former Employee.
Ann Gianola, MA, Manager, Medical Education Accreditation and Grant Development
Ms. Gianola has disclosed the following relationship with commercial interests: Actelion: Grant/Research Support.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations
Ms. Gregory has disclosed that she has no relevant financial relationships.
PrandoniPLensingAWPiccioliA. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood2002;100:3484–3488.
KhoranaAAFrancisCWCulakovaE. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost2007;5:632–634.
KhoranaAADalalMRLinJConnollyGC. Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clinicoecon Outcomes Res2013;5:101–108.
KhoranaAADalalMLinJConnollyGC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer2013;119:648–655.
MooreRAAdelNRiedelE. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol2011;29:3466–3473.
KhoranaAADalalMTangiralaKMiaoR. Higher incidence of venous thromboembolism in the outpatient versus the inpatient setting among U.S. cancer patients [abstract]. Blood2011;118:Abstract 674.
Di NisioMPorrecaEFerranteN. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev2012;2:CD008500.
VersoMGussoniGAgnelliG. Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC-2 studies. J Thromb Haemost2010;8:1649–1651.
KudererNMOrtelTLKhoranaAA. Low-molecular-weight heparin for venous thromboprophylaxis in ambulatory cancer patients: a systematic review meta-analysis of randomized controlled trials [abstract]. Blood2009;114:Abstract 490.
AgnelliGGeorgeDJKakkarAK. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med2012;366:601–609.
AgnelliGGussoniGBianchiniC. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol2009;10:943–949.
ZwickerJILiebmanHABauerKA. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol2013;160:530–537.
MaraveyasAWatersJRoyR. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer2012;48:1283–1292.
RiessHPelzerUHilbigA. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy. BMC Cancer2008;8:361.
RiessHPelzerUOpitzB. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy. Final results of the CONKO-004 trial [abstract]. J Clin Oncol2010;28(Suppl):Abstract 4033.
PerryJRJulianJALaperriereNJ. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost2010;8:1959–1965.
LaroccaACavalloFBringhenS. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood2012;119:933–939; quiz 1093.
PalumboACavoMBringhenS. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol2011;29:986–993.
KhoranaAAKudererNMCulakovaE. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood2008;111:4902–4907.
MandalaMClericiMCorradinoI. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the ‘SENDO experience.’Ann Oncol2012;23:1416–1421.
McGinnTGGuyattGHWyerPC. Users’ guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group. JAMA2000;284:79–84.
LymanGHKhoranaAAKudererNM. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol2013;31:2189–2204.
StreiffMBBockenstedtPLCatalandSR. NCCN Clinical Practice Guidelines in Oncology: Venous Thromboembolic Disease. Version 1.2003. Available at: NCCN.org. Accessed May 2 2013.
VersoMAgnelliGBarniS. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Int Emerg Med2012;7:291–292.
GeorgeDJAgnelliGFisherW. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVE-ONCO [abstract]. Presented at the 53rd ASH Annual Meeting and Exposition; December 10-13, 2011; San Diego, California. Abstract 206.
MandalaMFalangaARoilaF. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol2011;22(Suppl 6):vi85–92.
RicklesFRVargaEBrownsteinA. Deep vein thrombosis (DVT) and pulmonary embolism (PE): awareness and prophylaxis practices reported by patients with cancer [abstract]. J Clin Oncol2011;29(Suppl):Abstract 9101.
Le SageSMcGeeMEmedJD. Knowledge of venous thromboembolism (VTE) prevention among hospitalized patients. J Vasc Nurs2008;26:109–117.
LevineMNGuCLiebmanHA. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost2012;10:807–814.